CSPG4 and acute lymphoblastic leukemia: Because NG2 is a malleable marker with enhanced expression in blasts infiltrating extramedullar hematopoietic sites [18], we propose that a MoAb-based or chimeric antigen receptor (CAR) T-cell-based immunotherapy approaches will benefit current treatment of de novo or R/R MLLr-B-ALL patients.